
Monitoring signals governed from bedside to command center
Care teams can review vital-sign routing, alert ownership, device identity, and escalation windows before a connected monitoring pilot touches a live unit.
Medtronic helps hospital teams coordinate consumables, patient monitoring, and laboratory workflows through disciplined documentation, service escalation, and digital interoperability planning. Evaluation packets reference unique device identification (UDI), HL7 FHIR messaging, ISO 13485 quality-system controls, and market-specific 510(k) substantial equivalence or CE marked under MDR 2017/745 documentation—never as a blanket clearance claim for every SKU. Monitoring reviews also state SpO2 measurement acceptance ranges (0–100%, ±2% at 70–100%) when a product family publishes that performance envelope; claims outside a named indication, market, or interface version are out of scope.

Care teams can review vital-sign routing, alert ownership, device identity, and escalation windows before a connected monitoring pilot touches a live unit.

Supply chain leaders can align sterile kits, surgical smoke accessories, wound care products, and lot-level recall lookups with value analysis review.

Laboratory stakeholders receive validation checklists covering reagent stability, QC cadence, result routing, and middleware integration with existing systems.
| Review item | Clinical pilot track | Enterprise rollout track |
|---|---|---|
| Interoperability | FHIR observation test, HL7 v2 mapping, sample interface file | Capability statement, EMR governance, audit log export |
| Cybersecurity | SBOM review, MDS2 packet, CVE triage contact | Patch cadence, SIEM routing, coordinated disclosure SLA |
| Supply traceability | unique device identification (UDI) sample labels, lot lookup, expiry controls | GPO contract mapping, recall workflow, replenishment rules |
| Service model | Remote launch support, training session, escalation matrix | Installed-base PM plan, parts depot, field service mean time to repair (MTTR) dashboard |
| Evidence packet | Indication summary, IFU, risk-benefit analysis notes, training record | clinical evaluation report (CER) abstract, post-market surveillance (PMS) plan, market-specific regulatory references |
| Single-use vs reusable | single-use device (SUD) sterility assurance level (SAL) packet for ASC turnover | reprocessing validation under AAMI ST91 / ISO 17664 when a reusable path is selected |
Share the care setting, integration constraints, product family, and target launch date. The response will map documentation, stakeholders, and evaluation milestones.
Start Evaluation